Evaluation of ATOX1 as a potential predictive biomarker for tetrathiomolybdate treatment of breast cancer patients with high risk of recurrence
Journal article, 2021
ATOX1
Breast cancer
Tetrathiomolybdate
Clinical trial
Copper depletion
Biomarker
Event-free survival
Author
Stephanie Blockhuys
Chalmers, Biology and Biological Engineering, Chemical Biology
C. Hildesjo
Linköping University
Hans Olsson
Linköping University
Linda Vahdat
Memorial Sloan-Kettering Cancer Center
Pernilla Wittung Stafshede
Chalmers, Biology and Biological Engineering, Chemical Biology
Biomedicines
22279059 (eISSN)
Vol. 9 12 1887Disease mechanisms of copper chaperone Atox1
Swedish Research Council (VR) (2019-03673), 2020-01-01 -- 2024-12-31.
Subject Categories
Surgery
Urology and Nephrology
Cancer and Oncology
DOI
10.3390/biomedicines9121887
PubMed
34944703